Roquefort Therapeutics (LSE:ROQ) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Roquefort Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Roquefort Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Roquefort Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was £0.00 Mil.

Roquefort Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Roquefort Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Debt-to-Revenue Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	N/A	N/A	N/A	-	N/A

Competitive Comparison of Roquefort Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Roquefort Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Debt-to-Revenue falls into.

Roquefort Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Roquefort Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.2
	=	0.00

Roquefort Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Roquefort Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines